Historique
Périodique
Whither medical marijuana?
(Quelle place pour le cannabis thérapeutique ?)
Auteur(s) :
GRINSPOON, L.
Année
2000
Page(s) :
3-15
Langue(s) :
Anglais
Refs biblio. :
12
Domaine :
Drogues illicites / Illicit drugs
Discipline :
MAR (Marchés / Markets)
Thésaurus mots-clés
CANNABIS
;
USAGE THERAPEUTIQUE
;
PRODUCTION REGLEMENTEE
;
INDUSTRIE DU MEDICAMENT
;
MARCHE DE LA DROGUE
Note générale :
Contemporary Drug Problems, 2000, 27, (1), 3-15
Résumé :
FRANÇAIS :
Nous disposons de plus en plus d'éléments montrant la valeur thérapeutique du cannabis. En se projetant dans l'avenir, on peut se demander sous quelle forme il sera disponible en tant que médicament, et aussi quels en seront les circuits de production et de vente. Peut-on imaginer une production et une commercialisation contrôlée de cannabis au sein de l'industrie pharmaceutique ? Comment se positionnera ce nouveau marché parallèlement à celui du cannabis illicite ?
ENGLISH :
Given the very limited toxicity of cannabis and its increasingly acknowledged therapeutic value, it will undoubtedly find increasing application as a medicine in the coming years. But there is uncertainty about the forms in which it will be made available. Governments are unlikely to approve it because of concern about its use for nonmedical purposes and the difficulties of distributing as a medicine a substance that is already easily available. An alternative is the development of commercial cannabis pharmaceuticals that can be regulated and controlled, but pharmaceutical firms will be reluctant to invest the necessary money if they believe they cannot compete successfully with marijuana. Although some of these products may have advantages over whole smoked or ingested marijuana, most will not, and they will all be quite expensive. Ultimately, we can anticipate two medical distribution networks: a legal one for cannabinoid pharmaceuticals and an illegal one for street or homegrown marijuana. (Editor' s abstract)
Nous disposons de plus en plus d'éléments montrant la valeur thérapeutique du cannabis. En se projetant dans l'avenir, on peut se demander sous quelle forme il sera disponible en tant que médicament, et aussi quels en seront les circuits de production et de vente. Peut-on imaginer une production et une commercialisation contrôlée de cannabis au sein de l'industrie pharmaceutique ? Comment se positionnera ce nouveau marché parallèlement à celui du cannabis illicite ?
ENGLISH :
Given the very limited toxicity of cannabis and its increasingly acknowledged therapeutic value, it will undoubtedly find increasing application as a medicine in the coming years. But there is uncertainty about the forms in which it will be made available. Governments are unlikely to approve it because of concern about its use for nonmedical purposes and the difficulties of distributing as a medicine a substance that is already easily available. An alternative is the development of commercial cannabis pharmaceuticals that can be regulated and controlled, but pharmaceutical firms will be reluctant to invest the necessary money if they believe they cannot compete successfully with marijuana. Although some of these products may have advantages over whole smoked or ingested marijuana, most will not, and they will all be quite expensive. Ultimately, we can anticipate two medical distribution networks: a legal one for cannabinoid pharmaceuticals and an illegal one for street or homegrown marijuana. (Editor' s abstract)
Affiliation :
Harvard Med. School, 35 Skyline Drive, Wellesley, MA 02482, email: Igrinspmd@aol.com
Etats-Unis. United States.
Etats-Unis. United States.